RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Zacks.com on MSN14d
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These ...
ETF Daily News15d
IGM Financial (IGM) Scheduled to Release Earnings on Thursday
IGM Financial Price Performance Shares of IGM opened at C$42.85 on Thursday. The company has a debt-to-equity ratio of 35.99, a current ratio of 2.12 and a quick ratio of 0.31. The company’s ...
Intelligent Investor15d
Rhythm Biosciences Limited (ASX: RHY) - Share Price and Research
What is the current share price of Rhythm Biosciences Limited (RHY)? Rhythm Biosciences Limited's (RHY) current share price is $0.10. This constitutes a price movement of 9.09% when compared to the ...
Zacks.com on MSN15d
Amgen (AMGN) Beats Q3 Earnings Estimates
Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago. These figures are ...
pulsetasmania16d
Tasmanian tiger to roam again? Cartoons explain Colossal Biosciences’ de-extinction bid
Colossal Biosciences’ four-part ‘Tassie the tiger’ series hits screens today, exploring the thylacine, its importance to Tasmania and how de-extinction could work. Tasmanian Thylacine Advisory ...
University of Sheffield17d
Scientists uncover key mechanism in pathogen defence, paving way for new antimicrobial strategies
Researchers have made a significant breakthrough in understanding how certain pathogens defend themselves against the host's immune system. Active site of Streptococcus pyogenes Zn-Macro (purple ...